GBP/USD rose on Tuesday, climbing four-tenths of one percent on the day and testing the 1.3400 handle on headlines of a possible US-UK trade deal that would see the UK avoid the brunt of trade tariffs being actively pursued by the Trump admin.
Gold rallied to a two-week peak on Tuesday as the Chinese markets resumed operations following a long weekend holiday and concerns about US trade policies.
The AUD/USD pair remains resilient, despite a retreat from recent highs. The Australian Dollar benefits from a weaker US Dollar, as market participants focus on the Fed’s anticipated policy meeting on Wednesday.
At the start of the week, Goldman analysts and others told clients that Tesla's market share in China has remained stable, and the world's second-largest economy has recently overtaken the U.S. as Tesla's largest market.
It was a boring day, with the market falling to start and basically trading sideways. Tomorrow, of course, will be the FOMC meeting, and I do not expect anything material to come from it.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts’ estimates. Its GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Global professional services company Jacobs Solutions (NYSE:J) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.2% year on year to $2.91 billion. Its non-GAAP profit of $1.48 per share was 6.9% above analysts’ consensus estimates.
Health insurance company Clover Health (NASDAQ:CLOV) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its GAAP loss of $0 per share was significantly above analysts’ consensus estimates.
